Resistance to Immunotoxins in Cancer Therapy PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Resistance to Immunotoxins in Cancer Therapy PDF full book. Access full book title Resistance to Immunotoxins in Cancer Therapy by Rama Shanker Verma. Download full books in PDF and EPUB format.
Author: Rama Shanker Verma
Publisher: Springer
ISBN: 3319172751
Category : Medical
Languages : en
Pages : 259
Get Book Here
Book Description
This book will be a guide to understanding resistance against targeted therapeutic approaches for cancer using immunotoxins. It contains a detailed review of the history and development of targeted therapy. As well, it includes an in-depth description of the molecular and cellular mechanisms involved in cancer resistance and several novel methods to overcome resistance. Each chapter discusses different aspects of resistance and covers all the factors that may contribute to resistance in cancer cells. Finally, this volume highlights the recent findings and advances associated with tackling cancer resistance.
Author: Rama Shanker Verma
Publisher: Springer
ISBN: 3319172751
Category : Medical
Languages : en
Pages : 259
Get Book Here
Book Description
This book will be a guide to understanding resistance against targeted therapeutic approaches for cancer using immunotoxins. It contains a detailed review of the history and development of targeted therapy. As well, it includes an in-depth description of the molecular and cellular mechanisms involved in cancer resistance and several novel methods to overcome resistance. Each chapter discusses different aspects of resistance and covers all the factors that may contribute to resistance in cancer cells. Finally, this volume highlights the recent findings and advances associated with tackling cancer resistance.
Author: Haya Lorberboum-Galski
Publisher: CRC Press
ISBN: 0203216474
Category : Medical
Languages : en
Pages : 288
Get Book Here
Book Description
Bacteria and plants produce powerful toxins that can cause a variety of diseases, some of which are lethal for many animal species. The mechanisms of action are common to many of these toxins and represent general pathways for the interaction of a number of biomolecules with target cells, such as binding to specific surface receptors, internalizati
Author: Adam E. Snook
Publisher: MDPI
ISBN: 3036501908
Category : Science
Languages : en
Pages : 104
Get Book Here
Book Description
Cancer has been a patient-specific and difficult-to-treat disease for decades, resulting in more deaths since 1900 than all other diseases except cardiovascular diseases. As societies around the world continue to shift towards an aging population, the social and economic burden created by cancer will only rise in the coming decades, necessitating continued improvement in our cancer therapies. Remarkably, in the late 1800s, bone surgeon William Coley serendipitously discovered that bacteria could be administered to patients as an effective (and sometimes toxic) form of cancer therapy known as "Coley's Toxins". His discoveries unknowingly led to two fields of cancer therapy that have been in development for decades and are now leading to significant improvements in therapy for cancer patients: immune-based and toxin-based therapies for cancer. Articles included here discuss the discoveries that emerged from Coley's Toxins that enable us to harness the immune system and microbial toxins to combat cancers, as oncology shifts from a field dominated by chemotherapy for most of the 20th century to biologic therapies that will dominate the 21st century.
Author: Stewart Sell
Publisher: Springer Science & Business Media
ISBN: 1461251761
Category : Medical
Languages : en
Pages : 440
Get Book Here
Book Description
This represents the third volume in a series on cancer markers pub lished by the Humana Press. The first volume, published in 1980, stressed the relationship of development and cancer as reflected in the production of markers by cancer that are also produced by normal cells during fetal development. The concept that cancer represents a problem of differentiation was introduced by Barry Pierce in describing differenti ation of teratocarcinomas. Highlighted were lymphocyte markers, alphafetoprotein, carcinoembryonic antigen, ectopic hormones, enzymes and isozymes, pregnancy proteins, and fibronectin. The second volume, published in 1982 and coedited with Britta Wahren, focused on the diagnostic use of oncological markers in human cancers, which were systematically treated on an organ by organ basis. At that time, the application of monoclonal antibodies to the identification of cancer markers was still in a very preliminary stage. A general introduc tion to monoclonal antibodies to human tumor antigens was given there by William Raschke, and other authors included coverage of those mark ers then detectable by monoclonal antibodies in their chapters.
Author: John H. Sampson
Publisher: Academic Press
ISBN: 0128026251
Category : Medical
Languages : en
Pages : 406
Get Book Here
Book Description
Translational Immunotherapy of Brain Tumors gives researchers and practitioners an up-to-date and comprehensive overview of the field. Chapters include adoptive immunotherapy, immunosuppression, CAR therapy of brain tumors, and dendritic cell therapy for brain tumors. Very few agents have been shown to be efficacious in the treatment of malignant gliomas. Recently, there have been a number of studies demonstrating the potential success of immunotherapy for brain tumors. Immunotherapeutics are becoming the most frequent drugs to be used in cancer therapy. These new breakthroughs, now approved by the FDA, are a part of multiple phase III international trials and ongoing research in malignant glioma, meaning that the information in this cutting-edge book will be of great importance to practitioners and researchers alike. 2018 BMA Medical Book Awards Highly Commended in Oncology - Comprehensive overview, providing an update on immunology, translational immunotherapy, and clinical trials relating to malignant gliomas - Edited by a prominent neurosurgeon with contributions by leading researchers in the field - Ideal resource for researchers and practitioners interested in learning about mechanisms that use the immune system to treat brain tumors
Author: John Mendelsohn
Publisher: Elsevier Health Sciences
ISBN: 1437710999
Category : Medical
Languages : en
Pages : 1948
Get Book Here
Book Description
Successfully fighting cancer starts with understanding how it begins. This thoroughly revised 3rd Edition explores the scientific basis for our current understanding of malignant transformation and the pathogenesis and treatment of cancer. A team of leading experts thoroughly explain the molecular biologic principles that underlie the diagnostic tests and therapeutic interventions now being used in clinical trials and practice. Incorporating cutting-edge advances and the newest research, the book provides thorough descriptions of everything from molecular abnormalities in common cancers to new approaches for cancer therapy. Features sweeping updates throughout, including molecular targets for the development of anti-cancer drugs, gene therapy, and vaccines...keeping you on the cutting edge of your specialty. Offers a new, more user-friendly full-color format so the information that you need is easier to find. Presents abundant figures-all redrawn in full color-illustrating major concepts for easier comprehension. Features numerous descriptions of the latest clinical strategies-helping you to understand and take advantage of today’s state-of-the-art biotechnology advances.
Author: Benny K. C. Lo
Publisher: Springer Science & Business Media
ISBN: 1592596665
Category : Science
Languages : en
Pages : 555
Get Book Here
Book Description
The exquisite binding specificity of antibodies has made them valuable tools from the laboratory to the clinic. Since the description of the murine hybridoma technology by Köhler and Milstein in 1975, a phenomenal number of mo- clonal antibodies have been generated against a diverse array of targets. Some of these have become indispensable reagents in biomedical research, while others were developed for novel therapeutic applications. The attractiveness of an- bodies in this regard is obvious—high target specificity, adaptability to a wide range of disease states, and the potential ability to direct the host’s immune s- tem for a therapeutic response. The initial excitement in finding Paul Ehrlich’s “magic bullet,” however, was met with widespread disappointment when it was demonstrated that murine antibodies frequently elicit the human anti-murine an- body (HAMA) response, thus rendering them ineffective and potentially unsafe in humans. Despite this setback, advances in recombinant DNA techniques over the last 15–20 years have empowered the engineering of recombinant antibodies with desired characteristics, including properties to avoid HAMA. The ability to p- duce bulk quantities of recombinant proteins from bacterial fermentation also fueled the design of numerous creative antibody constructs. To date, the United States Food and Drug Administration has approved more than 10 recombinant antibodies for human use, and hundreds more are in the development pipeline. The recent explosion in genomic and proteomic information appears ready to deliver many more disease targets amenable to antibody-based therapy.
Author: Wolfgang Link
Publisher: Springer Nature
ISBN: 3030187225
Category : Medical
Languages : en
Pages : 156
Get Book Here
Book Description
This book explains how current medicines against cancer work and how we find new ones. It provides an easy-to-understand overview of current options to treat patients with cancer, which includes Surgery, Radiation therapy, Chemotherapy, Targeted therapy and Immunotherapy. The efficiency of all these treatments is limited by the capacity of cancer cells to escape therapy. This book explains the mechanisms of anti-cancer drug resistance and strategies to overcome it. The discovery and development process of a new drug is detailed beginning with the identification and validation of a therapeutic target, the identification of an inhibitor of the target and its subsequent preclinical and clinical development until its approval by regulatory authorities. Particular emphasis has been given to specific aspects of the development process including lead generation and optimization, pharmacokinetics, ADME analysis, pharmacodynamics, toxicity and efficacy assessment, investigational new drug (IND) and new drug application (NDA) and the design of clinical trial and their phases. The book covers many aspects of modern personalized oncology and discusses economic aspects of our current system of developing new medicines and its impact on our societies and on future drug research. The author of this book, Dr. Link counts with more than 20 years of experience in biomedical research reflected in numerous publications, patents and key note and plenary presentations at international conferences. Interested readers, students and teachers should read this book as it provides a unique way to learn/teach about basic concepts in oncology and anti-cancer drug research.
Author: F. Himmelweit
Publisher: Elsevier
ISBN: 1483139832
Category : Science
Languages : en
Pages : 678
Get Book Here
Book Description
The Collected Papers of Paul Ehrlich, Volume I covers topics on histology, biochemistry, and pathology. The book presents topics on practice and theory of staining in histology; cytology of the blood in health and disease; and the staining of bacteria and its application to diagnosis. The text also includes topics on the requirement of the organism for oxygen and other allied biochemical studies; pharmacology, therapeutics and toxicology; and the diazobenzenesulphonic acid and dimethylaminobenzaldehyde reactions.
Author: J. W. Westley
Publisher: CRC Press
ISBN: 9780367451929
Category :
Languages : en
Pages : 432
Get Book Here
Book Description
This collection of essays will stimulate the use of ionophores in different research areas. It includes information on potential breakthroughs in the halogenated derivatives of lasalocid and ethers of antibiotic A204A, polyethers and analytical techniques used to unravel their complex structures.
